ARWR
Arrowhead Pharmaceuticals, Inc.
October 14, 2026 · pre-market
- Rarity
- 1.89
- Peak move
- +9.44%
- Float cap
- $7.3B
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics for diseases with a genetic basis. Its first approved product, REDEMPLO (plozasiran), treats familial chylomicronemia syndrome, and the company has a pipeline targeting severe hypertriglyceridemia and other conditions. It also licenses its technology to pharmaceutical partners.
Where do you see this going?
no votes yetVote to see the split.
What we found
3 events · 0 from SEC or newswire · 1 timed with the move- Timed with the move
clinical_readoutArrowhead Pharmaceuticals reported interim Phase 1/2a data for ARO-MAPT in healthy volunteers, showing mean cerebrospinal fluid total tau reduction of up to 73% at Day 105 (max 85%) at 12.8 mg/kg dosed on Days 1 and 15, supporting quarterly subcutaneous dosing, with no serious adverse events.
peer_disclosureRoche signed a global exclusive license with Shanghai-based Rona Therapeutics for an investigational ALK7-targeting RNAi obesity therapy worth up to $1.16 billion, comprising $100 million upfront and up to $1.06 billion in milestones plus tiered royalties.
analyst_ratingJ.P. Morgan analyst Brian Cheng reiterated a Buy rating on Arrowhead Pharmaceuticals, dated September 2026 around the ARO-DIMER-PA interim data, maintaining a bullish stance on the DIMER platform.